ClinicalTrials.gg
CompletedNCT02791516Updated Oct 7, 2019Results posted

A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

A Phase 3 interventional study of Romosozumab and Placebo in Postmenopausal Osteoporosis, sponsored by Amgen. Completed at 10 sites in Korea, Republic of. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-10-07.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.

Enrollment
11th of 12
67 · median 268
Started
2017
the only one that year
Phase 3
6 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
9 of 12
Amgen

Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 11th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 3, and was the 7th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing romosozumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

The primary objective is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy X-ray absorptiometry (DXA) in postmenopausal women with osteoporosis.

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • Osteoporosis.
  • Osteoporosis-Postmenopausal.
  • Bone Diseases-Metabolic.
  • Bone Diseases.
  • Musculoskeletal Diseases.
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory Korean women, ≥ 55 to ≤ 90 years of age at enrollment.
  • Postmenopause is defined as no spontaneous vaginal bleeding or spotting for 12 or more consecutive months prior to screening.
  • BMD T-score \</= -2.50 at the lumbar spine, total hip or femoral neck.
  • At least 2 vertebrae in the L1 through L4 region and at least one hip are evaluable by DXA.
  • Other inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a BMD T-score \</= -4.0 at the lumbar spine, total hip, or femoral neck.
  • History of hip fracture.
  • Bone disease other than osteoporosis/ or evidence of any other disorder, condition/ or disease or significant laboratory abnormalities.
  • Known sensitivity or intolerance calcium and vitamin D products.
  • Other exclusion criteria may apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
67 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneous injection once a month for 6 months.

    Drug: Placebo

  • Experimental
    Romosozumab

    Participants received 210 mg romosozumab by subcutaneous injection once a month for 6 months.

    Drug: Romosozumab

Interventions

  • Administered by subcutaneous injection once a month (QM)

    Also known as: AMG 785, Evenity

  • DrugPlacebo

    Administered by subcutaneous injections once a month

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine

    Bone mineral density (BMD) at the lumbar spine was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.

    Time frame: Baseline and month 6

Secondary outcomes

  1. Percent Change From Baseline to Month 6 in Bone Mineral Density at the Total Hip

    Bone mineral density (BMD) at the total hip was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.

    Time frame: Baseline and month 6

  2. Percent Change From Baseline to Month 6 in Bone Mineral Density at the Femoral Neck

    Bone mineral density (BMD) at the femoral neck was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.

    Time frame: Baseline and month 6

07

Results

Posted Jul 5, 2019

Participant flow

This study was conducted at 10 centers in South Korea. Participants were enrolled from 16 January 2017 to 17 August 2017.

Participant flow — Overall Study
MilestonePlaceboRomosozumab 210 mg
Started3334
Completed 6-month treatment period3333
Completed3233
Not completed11
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryPercent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine

Bone mineral density (BMD) at the lumbar spine was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine
percent changePlaceboRomosozumab 210 mg
Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine-0.1 ± 0.89.5 ± 0.9
Statistical analysis
  • Placebo vs Romosozumab 210 mg · ANCOVA · p = <0.001 · Ls mean difference: 9.6 · 95% CI 7.6 to 11.5ANCOVA model adjusting for treatment, baseline DXA BMD value, machine type, and machine type-by-baseline DXA BMD value.
SecondaryPercent Change From Baseline to Month 6 in Bone Mineral Density at the Total Hip

Bone mineral density (BMD) at the total hip was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Month 6 in Bone Mineral Density at the Total Hip
percent changePlaceboRomosozumab 210 mg
Percent Change From Baseline to Month 6 in Bone Mineral Density at the Total Hip0.3 ± 0.42.9 ± 0.5
Statistical analysis
  • Placebo vs Romosozumab 210 mg · ANCOVA · p = <0.001 · Ls mean difference: 2.6 · 95% CI 1.4 to 3.7ANCOVA model adjusting for treatment, baseline DXA BMD value, machine type, and machine type-by-baseline DXA BMD value.
SecondaryPercent Change From Baseline to Month 6 in Bone Mineral Density at the Femoral Neck

Bone mineral density (BMD) at the femoral neck was assessed by dual-energy x-ray absorptiometry (DXA). Images were assessed by a central reader.

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Month 6 in Bone Mineral Density at the Femoral Neck
percent changePlaceboRomosozumab 210 mg
Percent Change From Baseline to Month 6 in Bone Mineral Density at the Femoral Neck0.8 ± 0.73.0 ± 0.6
Statistical analysis
  • Placebo vs Romosozumab 210 mg · ANCOVA · p = 0.004 · Ls mean difference: 2.2 · 95% CI 0.7 to 3.6ANCOVA model adjusting for treatment, baseline DXA BMD value, machine type, and machine type-by-baseline DXA BMD value.

Adverse events

Collected over 9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/33 (0%)2/33 (6.1%)4/33 (12.1%)
Romosozumab 210 mg0/34 (0%)0/34 (0%)2/34 (5.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboRomosozumab 210 mg
Pulmonary tuberculosisInfections and infestations1/330/34
Femur fractureInjury, poisoning and procedural complications1/330/34
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders1/330/34
Most frequent other events
Most frequent other events
EventPlaceboRomosozumab 210 mg
NasopharyngitisInfections and infestations2/331/34
Back painMusculoskeletal and connective tissue disorders2/331/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboRomosozumab 210 mgTotal
Mean68.4 ± 7.266.7 ± 7.667.5 ± 7.4
Age, Customized
Age, Customized(Participants)PlaceboRomosozumab 210 mgTotal
< 65 years131427
≥ 65 to < 75 years131629
≥ 75 years7411
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRomosozumab 210 mgTotal
Female333467
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRomosozumab 210 mgTotal
Asian333467
Lumbar Spine Bone Mineral Density (BMD) T-score
Lumbar Spine Bone Mineral Density (BMD) T-score(T-score)PlaceboRomosozumab 210 mgTotal
Mean-2.6483 ± 0.6450-2.6622 ± 0.8155-2.6554 ± 0.7310
Total Hip BMD T-score
Total Hip BMD T-score(T-score)PlaceboRomosozumab 210 mgTotal
Mean-2.1797 ± 0.6243-2.1515 ± 0.7114-2.1654 ± 0.6650
Femoral Neck BMD T-score
Femoral Neck BMD T-score(T-score)PlaceboRomosozumab 210 mgTotal
Mean-2.5309 ± 0.5395-2.4494 ± 0.6069-2.4896 ± 0.5718
08

Study locations

10 sites
  • Research Site
    Busan, 602-739, Korea, Republic of
  • Research Site
    Gwangju, 501-757, Korea, Republic of
  • Research Site
    Namdong-gu, Incheon, 21565, Korea, Republic of
  • Research Site
    Seongnam Si Gyeonggi Do, 463-707, Korea, Republic of
  • Research Site
    Seoul, 120-752, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Seoul, 136-705, Korea, Republic of
  • Research Site
    Seoul, 138-736, Korea, Republic of
  • Research Site
    Seoul, 150-713, Korea, Republic of
  • Research Site
    Suwon-si, Gyeonggi-do, 443-380, Korea, Republic of
09

References and documents

Publications

  • Baek KH, Chung YS, Koh JM, Kim IJ, Kim KM, Min YK, Park KD, Dinavahi R, Maddox J, Yang W, Kim S, Lee SJ, Cho H, Lim SK. Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study. Endocrinol Metab (Seoul). 2021 Feb;36(1):60-69. doi: 10.3803/EnM.2020.848. Epub 2021 Feb 24. PubMed 33677928 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Feb 2018, 12 months.

Results were first posted in Jul 2019, 1 year 4 months after primary completion. A results delay was requested in Dec 2018.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 12 months is below that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2016
First posted
Jun 6, 2016
StartActual
Jan 16, 2017
Primary completionActual
Feb 12, 2018
CompletionActual
Dec 21, 2018
Results delay requested
Dec 3, 2018
Results first posted
Jul 5, 2019
Last update
Oct 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02791516
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 6, 2016
Start date
Jan 16, 2017
Primary completion
Feb 12, 2018
Completion
Dec 21, 2018
Results posted
Jul 5, 2019
Last update
Oct 7, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion